UK Life Sciences Company Directory

TCR bispecific immunotherapies for cancer and infectious disease

Immunocore is a commercial-stage biopharma developing T cell receptor bispecific immunotherapies. Its lead product tebentafusp received FDA approval in 2022 for metastatic uveal melanoma and generated $400 million in revenue in 2025. Three Phase 3 trials are enrolling across melanoma indications, with topline data…

UK's largest early-phase clinical CRO specialising in first-in-human trials

Hammersmith Medicines Research is one of the largest early-phase contract research organisations in Europe, specialising in Phase I and early Phase II clinical trials of investigational medicinal products. Operating from a purpose-built 145-bed facility in West London, HMR provides fully integrated services from study…

Separation, purification, and sample preparation tools for life science workflows

Biotage GB is the UK subsidiary of Biotage AB, a Swedish life science tools group with manufacturing roots in Wales dating to 1969. Operating from facilities in Ystrad Mynach and Cardiff, the company designs and manufactures flash purification instruments and columns, solid phase extraction cartridges, and automated…

Bispecific TCR therapies targeting HLA-Class II cancer antigens

Yellowstone Biosciences is a pre-clinical biotechnology company developing bispecific T-cell receptor therapies for oncology. The company targets a novel class of HLA Class II antigens expressed across multiple cancers, with an initial programme focused on acute myeloid leukaemia. Its approach is designed to…

Oral muscle-sparing small molecule therapies for obesity

Hawkhill Therapeutics is a pre-clinical biotechnology company developing oral, muscle-sparing therapeutics for obesity and metabolic health. Its programme targets a clinically validated mechanism to achieve fat-selective weight loss while preserving muscle mass, addressing a recognised limitation of current GLP-1…

TSG-6 protein therapeutics for inflammatory and degenerative disease

Link Biologics is a preclinical-stage biotechnology company developing protein therapeutics based on TSG-6, an endogenous human protein with anti-inflammatory and tissue-protective properties. Spun out from the University of Manchester in 2021, the company is advancing its lead asset, Link_TSG6, across programmes in…

Cambridge cancer research institute advancing discovery and clinical translation

Cancer Research UK Cambridge Institute is a cancer research institute within the University of Cambridge, investigating tumour biology, early detection and treatment. Its research groups study cancer evolution, genomics and the tumour microenvironment, using imaging and computational approaches to improve diagnosis…

E3 ligase inhibitors stabilising tumour suppressor proteins

Outrun Therapeutics is a preclinical drug discovery company developing small molecule inhibitors of E3 ligase enzymes to stabilise tumour suppressor and other disease-relevant proteins. Its proprietary platform has been used to profile over 45 E3 ligases across oncology, cardiovascular, neurological, and autoimmune…

Automated liquid handling and sample management instruments

SPT Labtech is a designer and manufacturer of laboratory automation instruments and consumables for liquid handling, sample preparation, and sample management. Its product portfolio includes nanolitre liquid handling systems for drug discovery and genomics workflows, cryo-electron microscopy sample preparation…

Antibody immunotherapy targeting toxic tau for neurodegenerative disease

TauC3 Biologics is a preclinical biopharmaceutical company developing an antibody-based immunotherapy that targets tauC3, a toxic, truncated form of the tau protein implicated in neurodegenerative disease. Its lead candidate, TBL-100, is a humanized monoclonal antibody developed with LifeArc, designed to selectively…

Antibody therapeutics targeting glycosphingolipid inflammation

Protalea Bio is a biotech company developing first-in-class therapeutic antibodies to prevent progression from precancerous states to active blood cancers including multiple myeloma and B-cell lymphoma. The company's approach targets glycosphingolipid-related inflammation before disease onset, building on over fifteen…

Structure-guided small-molecule therapeutics for antiviral and metabolic diseases

Halo Therapeutics is a University of Bristol spinout developing structure-guided small-molecule medicines for infectious and metabolic diseases. Its research combines cryo-electron microscopy, protein biophysics and computational chemistry to identify drug-binding pockets and design selective compounds. Its antiviral…

G-quadruplex-targeting medicines for precision cancer treatment

Genome Therapeutics is a biotechnology company developing cancer medicines that target G-quadruplex DNA structures associated with tumour biology. Its approach builds on research into non-canonical DNA folding and how these structures influence gene regulation and cancer cell vulnerabilities. The company develops…

Clinical-stage peptide therapeutics for autoimmune and infectious disease

ImmuPharma is a clinical-stage biopharmaceutical company developing peptide-based therapeutics and precision diagnostics for autoimmune disease, infectious disease and metabolic disorders. Its lead candidate, a first-in-class immunormalizer for lupus, has completed a Phase III pivotal trial, aiming to restore normal…

Lab-grown human skin equivalent for cosmetic and pharmaceutical testing

Labskin is a contract research organisation offering preclinical testing services built around a proprietary full-thickness, lab-grown human skin equivalent. The model incorporates primary human keratinocytes and fibroblasts and is uniquely capable of hosting the skin's natural microflora, enabling microbiome-relevant…

CASPAROV AI platform for targets in heterogeneous cancers

Enedra Therapeutics develops targeted cancer medicines designed to address genetic diversity within solid tumours, a major cause of treatment resistance. Its CASPAROV platform combines cancer genomics, AI and functional biology to identify survival mechanisms shared across heterogeneous tumour cells. These convergent…

Engineered bacteriophages for precision antimicrobial discovery

BioPhoundry is an engineering biology company developing bacteriophage-based technologies for precision antimicrobial research. Its Phax platform combines machine learning, synthetic biology and cell-free production to accelerate phage discovery and engineering. The company aims to generate tailored phages for…

RNAi therapeutics for Parkinson's and neurodegenerative diseases

Valaya Bio is developing RNA interference (RNAi) therapeutics for age-related neurodegenerative diseases, initially Parkinson's disease. Its platform uses precision oligonucleotides designed to modulate upstream molecular regulators implicated in multiple disease pathways, including mitochondrial dysfunction,…

AI-guided plant biosynthesis platform for novel therapeutic compounds

HotHouse Therapeutics is a drug discovery platform company that engineers plants as sustainable biofactories for pharmaceutical compound production. Using AI to design and optimise biosynthetic pathways, it produces both natural and new-to-nature molecules via transient and stable plant expression systems capable of…

Not-for-profit research organisation targeting intrinsically disordered proteins

Bind Research is the UK's first Focused Research Organisation, established to make intrinsically disordered proteins druggable targets for new medicines. The organisation integrates NMR spectroscopy, biophysical characterisation, chemoproteomics, and AI to build comprehensive datasets of disordered protein-small…